University Home | Hospital | Pulse Employment | Contact Us | Search | News 
Thomas Jefferson University Search Jefferson
Jefferson Medical College Jefferson College of Graduate Studies Jefferson College of Health Professions
Menu

Thomas Jefferson University - David A. Berd
David A. Berd

Medical Oncology
Thomas Jefferson University
Jefferson Medical College
Department of Medical Oncology
Professor

Image Placeholder
Mailing Address
1015 Walnut Street
Philadelphia, Pennsylvania 19107
United States
Contact Information
Phone: (215) 955-8875
david.berd@jefferson.edu
Qualifications
M.D.,

Expertise and Research Interests
Histologically these responses arecharacterized by infiltration of the tumors with T Iymphocytes. In severalof these patients, we observed clinically-defined tumor regression, including a complete remission of extensive lung metastases. Furthermore, a high percentage of patients who received the vaccine after resection ofbulky lymph node metastases have remained alive and disease-free. In thisrenewal application, we propose to extend the clinical trials and toconduct laboratory studies of the T cells infiltrating DNP-vaccine-treatedmetastases. Patients with measurable metastases will be treated by a new, more intensive program that involves weekly administration of vaccinepreceded by a single dose of cyclophosphamide. Metastases that developedinflammation will be excised and cryopreserved. We will determine whetherthe infiltrating T cells have a characteristic phenotype or lymphokineprofile; the latter will be studied by a polymerase chain reaction PCR- based technique. We hypothesize that T cells found in regressing tumorswill have the TH1 profile, producing lL-2 and gamma interferon, but notthe anti-inflammatory lymphokines, lL-4 and lL-10. PCR will also be usedto characterize the T cell receptor variable TCR-V regions on these Tcells; we predict that the TCR-V repertoire will be restricted, suggestingthat the T cells are responding to a limited number of melanoma antigens. In another project, those T cells will be cloned by limiting dilution, andthe clones will be studied for autologous melanoma reactivity, bothcytotoxicity and lymphokine production. Finally, we will study clones ofPBL and T cells from DNP-vaccine injection sites to determine whether DNP- modified melanoma cells elicit responses that are distinct from thoseelicited by DNP-modified lymphocytes. We expect these studies to lead toadvances in the treatment of human melanoma and a better understanding ofthe immunobiology of that disease.
Keywords
Cancer; Cancer Biology; Cancer Prevention; Carcinogenesis; Cellular Immunity; Cellular Oncology; Clinical Trial; Cyclophosphamide; Human Subject; Human Therapy Evaluation; Immunoconjugate; Immunotherapy; Interleukin; Melanoma; Metastasis; Neoplasm Cancer Chemotherapy; Neoplasm Cancer Immunotherapy; Neoplasm Cancer Remission Regression; Neoplasm Cancer Vaccine; Polymerase Chain Reaction; Suppressor T Lymphocyte
Publications
  • Nathan FE; Berd D; Sato T; Mastrangelo MJ. Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma. Cancer. 88(1): 79-87, 1 2000

  • Dunton CJ; Berd D. Vulvar melanoma, biologically different from other cutaneous melanomas. Lancet. 354(9195): 2013-4, 11 Dec 1999

  • Berd D; Kairys J; Dunton C; Mastrangelo MJ; Sato T; Maguire HC Jr. Autologous, hapten-modified vaccine as a treatment for human cancers. Seminars in Oncology. 25(6): 646-53, Dec 1998

  • Sensi M;Farina C;Maccalli C;Anichini A;Berd D;Parmiani G. Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination. Journal of Immunotherapy. 21(3): 198-204, May 1998

  • McClay E F;Berd D;Mastrangelo M J. The Dartmouth Regimen: gone or going strong? [editorial; comment]. Cancer Investigation. 16(6): 421-3, 1998

  • Mastrangelo M J;Sato T;Lattime E C;Maguire H C Jr;Berd D. Cellular vaccine therapies for cancer. Cancer Treatment and Research. 94: 35-50, 1998

  • Sato T;Bullock T N;Eisenlohr L C;Mastrangelo M J;Berd D. Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides. Clinical Immunology and Immunopathology. 85(3): 265-72, Dec 1997

  • Nathan F E;Berd D;Sato T;Shield J A;Shields C L;De Potter P;Mastrangelo M J. BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. Journal of Experimental and Clinical Cancer Research. 16(2): 201-8, Jun 1997

  • Berd D;Maguire H C Jr;Schuchter L M;Hamilton R;Hauck W W;Sato T;Mastrangelo M J. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. Journal of Clinical Oncology. 15(6): 2359-70, Jun 1997

  • Sensi M;Farina C;Maccalli C;Lupetti R;Nicolini G;Anichini A;Parmiani G;Berd D. Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. Journal of Clinical Investigation. 99(4): 710-7, 15 Feb 1997

  • Mastrangelo M J;Maguire H C Jr;Sato T;Nathan F E;Berd D. Active specific immunization in the treatment of patients with melanoma. Seminars In Oncology. 23(6): 773-81, Dec 1996

  • Sato T; McCue P; Masuoka K; Salwen S; Lattime EC; Mastrangelo MJ; Berd D. Interleukin 10 production by human melanoma. Clinical Cancer Research. 2(8): 1383-90, Aug 1996

  • Berd D;Mastrangelo M J;Lattime E;Sato T;Maguire H C Jr. Melanoma and vitiligo: immunology's Grecian urn. Cancer Immunology, Immunotherapy. 42(5): 263-7, Jun 1996

  • Ohta M;Berd D;Shimizu M;Nagai H;Cotticelli M-G;Mastrangelo M;Shields J A;Shields C L;Croce C M;Huebner K. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. International Journal of Cancer. 65(6): 762-7, 15 Mar 1996

  • Huebner K;Ohta M;Lubinski J;Berd D;Maguire H C Jr. Detection of specific genetic alterations in cancer cells. Seminars In Oncology. 23(1): 22-30, Feb 1996

  • Mastrangelo M J;Berd D;Nathan F E;Lattime E C. Gene therapy for human cancer: an essay for clinicians. Seminars In Oncology. 23(1): 4-21, Feb 1996

  • Berd D;Parmiani G. Human tumor vaccines go molecular. Summary of American Association for Cancer Research Symposium, March 20,1995. Cancer Immunology, Immunotherapy. 41(3): 199-200, Sep 1995

  • Lattime E C;Mastrangelo M J;Bagasra O;Li W;Berd D. Expression of cytokine mRNA in human melanoma tissues. Cancer Immunology, Immunotherapy. 41(3): 151-6, Sep 1995

  • Berd D;Mastrangelo M J. Combination chemotherapy of metastatic melanoma [letter; comment]. Journal of Clinical Oncology. 13(3): 796-7, Mar 1995

  • Sato T;Maguire H C Jr;Mastrangelo M J;Berd D. Human immune response to DNP-modified autologous cells after treatment with a DNP-conjugated melanoma vaccine. Clinical Immunology and Immunopathology. 74(1): 35-43, Jan 1995

  • Cohen I R;Murdoch A D;Naso M F;Marchetti D;Berd D;Iozzo R V. Abnormal expression of perlecan proteoglycan in metastatic melanomas. Cancer Research. 54(22): 5771-4, 15 Nov 1994

  • Ohta M;Nagai H;Shimizu M;Rasio D;Berd D;Mastrangelo M;Singh A D;Shields J A;Shields C L;Croce C M;et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Research. 54(20): 5269-72, 15 Oct 1994

  • Berd D;Maguire H C Jr;Mastrangelo M J;Murphy G. Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine. Cancer Immunology, Immunotherapy. 39(3): 141-7, Sep 1994

  • Berger R;Albelda S M;Berd D;Ioffreda M;Whitaker D;Murphy G F. Expression of platelet-endothelial cell adhesion molecule-1 (PECAM-1) during melanoma-induced angiogenesis in vivo. Journal of Cutaneous Pathology. 20(5): 399-406, Oct 1993

  • Berd D;Maguire H C Jr;Mastrangelo M J. Treatment of human melanoma with a hapten-modified autologous vaccine. Annals of The New York Academy of Sciences. 690: 147-52, 12 Aug 1993

  • Murphy G F;Radu A;Kaminer M;Berd D. Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: relevance to immunologic regression and immunotherapy. Journal of Investigative Dermatology. 100(3): 335S-341S, Mar 1993

  • McClay E F;Mastrangelo M J;Berd D;Bellet R E. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. International Journal of Cancer. 50(4): 553-6, 20 Feb 1992

  • Hill L L;Korngold R;Jaworsky C;Murphy G;McCue P;Berd D. Growth and metastasis of fresh human melanoma tissue in mice with severe combined immunodeficiency. Cancer Research. 51(18): 4937-41, 15 Sep 1991

  • Berd D;Murphy G;Maguire H C Jr;Mastrangelo M J. Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Research. 51(10): 2731-4, 15 May 1991

  • McLean I W;Berd D;Mastrangelo M J;Shields J A;Davidorf F H;Grever M;Makley T A;Gamel J W. A randomized study of methanol-extraction residue of bacille Calmette-Guerin as postsurgical adjuvant therapy of uveal melanoma. American Journal of Ophthalmology. 110(5): 522-6, 15 Nov 1990

  • Berd D;Maguire H C Jr;McCue P;Mastrangelo M J. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. Journal of Clinical Oncology. 8(11): 1858-67, Nov 1990

  • Schultz S;Kane M;Roush R;Miller V;Berd D;Goldman L;Mastrangelo M. Time to recurrence varies inversely with thickness in clinical stage 1 cutaneous melanoma. Surgery, Gynecology and Obstetrics. 171(5): 393-7, Nov 1990

  • Berd D. Low doses of chemotherapy to inhibit suppressor T cells. Progress In Clinical and Biological Research. 288: 449-58, 1989

Individual Expertise profile of David A. Berd, Copyright © David A. Berd.
Last Updated by Admin : Monday, January 8, 2007 3:35:31 PM



Maintained by Jefferson Information Technologies
Copyright © Thomas Jefferson University. All Rights Reserved.

 Printable Version

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement.
Thomas Jefferson University